Literature DB >> 259421

Antibiotic activity in vitro against methicillin-resistant Staphylococcus epidermidis and therapy of an experimental infection.

F D Lowy, J A Walsh, M M Mayers, R S Klein, N H Steigbigel.   

Abstract

Staphylococcus epidermidis is a major pathogen in early prosthetic valve endocarditis and cerebrospinal fluid shunt infections. Approximately 10 to 15% of hospital isolates are methicillin resistant. Ten clinically significant isolates of the latter were collected for antibiotic studies in vitro and in an experimental infection in animals. Time-kill studies of five strains showed gentamicin to be the single most effective antibiotic; however, dwarf colony variants emerged as survivors with two of these strains when challenged with gentamicin alone. The addition of a second antibiotic to gentamicin did not significantly improve the bactericidal rate but prevented the emergence of variant strains. A blood culture isolate of methicillin-resistant S. epidermidis combined with 5% hog gastric mucin was used to establish an experimental intraperitoneal infection in mice. Neither methicillin nor nafcillin treatment reduced mortality below that of untreated animals. Cephalothin treatment delayed early mortality but did not diminish overall mortality. Gentamicin was the most effective single antibiotic, and gentamicin in combination with vancomycin was the most effective regimen overall. The combination of rifampin plus vancomycin was as effective as gentamicin alone. The combinations of cephalothin or nafcillin with gentamicin and cephalothin with vancomycin demonstrated antagonism. The antagonism was not due to multiple injections or drug-drug inactivation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 259421      PMCID: PMC352852          DOI: 10.1128/AAC.16.3.314

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  IN VITRO ACTIVITY OF PENICILLINS AGAINST STAPHYLOCOCCUS ALBUS.

Authors:  J O KJELLANDER; J O KLEIN; M FINLAND
Journal:  Proc Soc Exp Biol Med       Date:  1963 Aug-Sep

2.  MUCIN AS A RESISTANCE-LOWERING SUBSTANCE.

Authors:  L Olitzki
Journal:  Bacteriol Rev       Date:  1948-06

3.  Further observations on the zone phenomenon in the bactericidal action of penicillin.

Authors:  H EAGLE
Journal:  J Bacteriol       Date:  1951-11       Impact factor: 3.490

4.  Infective endocarditis: a review of 125 cases from the University of Washington Hospitals, 1963-72.

Authors:  L L Pelletier; R G Petersdorf
Journal:  Medicine (Baltimore)       Date:  1977-07       Impact factor: 1.889

5.  Antibiotic susceptibility of oxacillin-resistant staphylococci.

Authors:  J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1972-05       Impact factor: 5.191

6.  Methicillin resistance in Staphylococcus epidermidis epidemiologic studies.

Authors:  D W Bentley
Journal:  Contrib Microbiol Immunol       Date:  1973

7.  Gentamicin treatment of staphylococcal infections.

Authors:  F Richards; C McCall; C Cox
Journal:  JAMA       Date:  1971-02-22       Impact factor: 56.272

8.  Methicillin resistance of Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  L D Sabath; F F Barrett; C Wilcox; D A Gerstein; M Finland
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

9.  In vitro activity of cephalosporins against methicillin-resistant, coagulase-negative staphylococci.

Authors:  M Laverdiere; P Peterson; J Verhoef; D N Williams; L D Sabath
Journal:  J Infect Dis       Date:  1978-03       Impact factor: 5.226

10.  Antimicrobial susceptibility and selection of resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices.

Authors:  G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

View more
  10 in total

1.  Local release of antibiotics for surgical site infection management using high-purity calcium sulfate: an in vitro elution study.

Authors:  Sean S Aiken; John J Cooper; Hannah Florance; Matthew T Robinson; Stephen Michell
Journal:  Surg Infect (Larchmt)       Date:  2014-08-22       Impact factor: 2.150

2.  In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci.

Authors:  M Arditi; R Yogev
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  Comparison of antimicrobial susceptibility patterns among coagulase-negative staphylococci.

Authors:  S B Price; D J Flournoy
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

Review 4.  Current status of antibiotic prophylaxis in surgical patients.

Authors:  D N Gilbert
Journal:  Bull N Y Acad Med       Date:  1984-05

5.  Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci.

Authors:  F D Lowy; D S Chang; P R Lash
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

Review 6.  Cephalosporins in gram-positive infections.

Authors:  J Symonds; A M Geddes
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Detection of methicillin-resistant Staphylococcus epidermidis.

Authors:  G L Woods; G S Hall; I Rutherford; K J Pratt; C C Knapp
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

8.  Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans group and enterococcal streptococci.

Authors:  M H Miller; M A el-Sokkary; S A Feinstein; F D Lowy
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

9.  Staphylococcus aureus binding to human nasal mucin.

Authors:  J Shuter; V B Hatcher; F D Lowy
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

10.  Experimental foreign body infections in mice challenged with slime-producing Staphylococcus epidermidis.

Authors:  G D Christensen; W A Simpson; A L Bisno; E H Beachey
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.